現在のページ: 業務分野 / ライフサイエンス及び医療
ライフサイエンス及び医療

当事務所は、ライフサイエンス及び医療分野において豊富な実務経験を有しており、クライアントのビジネスニーズ及び法的ニーズの両方を満たすことができる法的サービスを提供しています。ライフサイエンス及び医療分野に特化した専門性の高い弁護士チームによる、法的コンプライアンスを重視した、シンプルかつ実行可能なプランや最善のアドバイスを提供することで、クライアントからの厚い信頼を得ています。

 

同チームは、中国のライフサイエンス及び医療事業に関する法律知識に富んでおり、その複雑なビジネス環境について造詣が深い弁護士を多数擁しています。また、同分野に関連する業界団体とも密接な連携関係があり、それらの組織・委員会のメンバーとして、関連業界の準則(行動規範)の制定に参加した実績もあります。

 

同弁護士チームは、医薬品の研究開発、臨床試験、製薬、ライフサイエンス、動物用医薬品、バイオ医薬品、医療機器、卸売・小売、医療機関及びその他の医療サービス業者、並びに当該分野への投資等、ライフサイエンス及び医療産業に関する全面的な法的サービスをクライアントに提供することができます。また、同弁護士チームは、本分野に関わるコンプライアンス法務においては業界トップの地位を占めています。

 

同チームは、公立病院の体制改革、非公立医療機関の形態変更などの複雑な案件の処理に長けており、クライアントの実情に合う、カスタマイズされた解決案を提案し、クライアントのビジネス目標の達成をサポートしています。

本分野における主に取扱い業務は以下のとおりです。

  • コンプライアンスに関する提案及びレビュー
  • 取引に関するプランニング及び交渉サポート
  • 製品ライン及び市場エリアの拡大
  • プロジェクトファイナンス、M&A、事業再編
  • 知的財産の保護
  • 許諾契約及び販売代理店契約
  • 臨床試験及び有害事象の紛争解決等

代表的な取扱い事例

  • Represented NFC to acquire United Family Healthcare, Deals of the Year - 2019 China Business Law Journal
  • Represented Novartis to acquire GlaxoSmithKline in the field of tumor, which is one of the largest M&A deals in global Life science and healthcare industry in 2015
  • Represented Zhejiang Tianyuan Bio Pharmaceutical Co., Ltd to sell its controlling shares to Novartis in Switzerland, which is the first foreign capital to enter the field of human vaccine through the acquisition of controlling shares
  • Represented China Resources Pharmaceutical Group and Beijing Municipal Government to reorganise Beijing BeiYao group, involving assets of about 50 billion yuan, four listed companies, which is the largest M & A transaction in China life science and healthcare industry
  • Represented BeiGenes (NASDAQ listed company) and Amgen (NASDAQ listed company) to complete a major transaction in the field of biomedicine
  • Represented BeiGene (NASDAQ listed company) and Celgene (NASDAQ listed company) to accomplish a strategic transaction globally relative to oncologic sector of Celgene
  • Represented Siemens Group to complete the initial listing offering (IPO) of its medical business sector - Siemens Healthcare AG in Frankfurt Stock Exchange (the largest IPO in the European market in 2018)

外部機構・団体からの評価

Full-service powerhouse firm that offers long-standing experience in the healthcare sector, working with high-profile domestic and international clients from start-ups to global pharmaceutical corporates. Widely recognised for its expertise assisting clients in the pharmaceutical and medical arenas on M&A, joint ventures, funding, licensing and regulatory matters. Additionally, the team advises private equity funds and other investors on various investment deals. Well placed to handle internal and government investigations as well as anti-bribery matters in the health sector. Offers customised services and ably tackles an increasing amount of compliance mandates. The practice also contributes to research projects and advises on legislative procedures relating to healthcare regulations.
—Chambers and Partners Asia-Pacific 2020

 

What the team is known for Full-service powerhouse firm that offers longstanding experience in the healthcare sector, working with high-profile domestic and international clients from start-ups to global pharmaceutical corporates. Widely recognised for its expertise assisting clients in the pharmaceutical and medical arenas on M&A, joint ventures, funding, licensing and regulatory matters. Additionally, the team advises private equity funds and other investors on various investment deals. Well placed to handle internal and government investigations as well as anti-bribery matters in the health sector. Demonstrates wider strengths in areas including dispute settlement and compliance programmes. The practice also contributes to research projects and advises on legislative procedures relating to healthcare regulations.
—Chambers and Partners Asia-Pacific 2021

 

Recognitions

Strengths Clients laud the team for " having a very comprehensive grasp of relevant laws, regulations and the latest changes as well as handling risks with flexibility in negotiations."
—Chambers and Partners Asia-Pacific 2021

 

受賞歴

  • 2018-2020, ALB China Law Awards: Healthcare Law Firm of the Year, Asian Legal Business
  • 2015-2016, 2018-2020, Healthcare & Life Sciences Law Firm of the Year for several times, LEGALBAND
  • 2016, 2018-2020, Healthcare PRC Law Firm of the Year for several times, China Business Law Journal
  • 2013-2016, 2018, 2020 Healthcare & Life Sciences PRC Law Firm of the Year, China Law & Practice
  • 2019, Deals of the Year: NFC acquires United Family Healthcare, China Business Law Journal
  • 2020, Best Business Development Service, the 15th China Pharmaceutical and Medtech Business Development Forum (CHBD Forum)
  • 2012, Healthcare Law firm of the year, Acquisition International

Rankings

  • 2013-2021, Band 1 firm in Healthcare, Chambers and Partners Asia Pacific
  • 2018-2020, Top-tier firm in Healthcare and Life Sciences, The Legal 500 Asia Pacific
  • 2019-2021, Recommended firm in Pharmaceuticals and life sciences, Asialaw Profiles
  • 2016-2020, Top-tier firm in Healthcare & Life Sciences, LEGALBAND